[go: up one dir, main page]

PE20181374A1 - Formulacion de combinacion farmaceutica - Google Patents

Formulacion de combinacion farmaceutica

Info

Publication number
PE20181374A1
PE20181374A1 PE2018001203A PE2018001203A PE20181374A1 PE 20181374 A1 PE20181374 A1 PE 20181374A1 PE 2018001203 A PE2018001203 A PE 2018001203A PE 2018001203 A PE2018001203 A PE 2018001203A PE 20181374 A1 PE20181374 A1 PE 20181374A1
Authority
PE
Peru
Prior art keywords
candesartan
pharmaceutical combination
combination formulation
hydroxiestearate
cilexetilo
Prior art date
Application number
PE2018001203A
Other languages
English (en)
Inventor
Jei-Man Ryu
Woo-Ile Park
Kyoung-Hwan Kang
Woo-Kyung Kim
Ah-Reum Chae
Soo-Won Kim
Hyun-Woo Jung
Jae-Young Lee
Original Assignee
Shin Poong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58543052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shin Poong Pharmaceutical Co Ltd filed Critical Shin Poong Pharmaceutical Co Ltd
Publication of PE20181374A1 publication Critical patent/PE20181374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE UNA TABLETA QUE COMPRENDE: A) UN PRIMER PRINCIPIO ACTIVO TAL COMO CANDESARTAN O CANDESARTAN CILEXETILO; B) UN SEGUNDO PRINCIPIO ACTIVO TAL COMO AMLODIPINA; Y C) UN SOLUBILIZANTE TAL COMO MACROGOL-15-HIDROXIESTEARATO; EN LA QUE LA RELACION EN PESO DE CANDESARTAN O CANDESARTAN CILEXETILO A MACROGOL-15-HIDROXIESTEARATO ES DE 1:0.03 A 1:2. DICHA FORMULACION ES UNA TABLETA DE DOBLE CAPA COMPUESTA POR UNA PRIMERA CAPA QUE CONTIENE CANDESARTAN O CANDESARTAN CILEXETILO CON MACROGOL-15-HIDROXIESTEARATO, Y UNA SEGUNDA CAPA QUE CONTIENE AMLODIPINA
PE2018001203A 2015-12-28 2016-12-28 Formulacion de combinacion farmaceutica PE20181374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150187679A KR101710441B1 (ko) 2015-12-28 2015-12-28 안정성 및 용출성이 향상된 정제

Publications (1)

Publication Number Publication Date
PE20181374A1 true PE20181374A1 (es) 2018-08-28

Family

ID=58543052

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001203A PE20181374A1 (es) 2015-12-28 2016-12-28 Formulacion de combinacion farmaceutica

Country Status (14)

Country Link
US (1) US20190015339A1 (es)
EP (1) EP3398589B1 (es)
JP (1) JP6797924B2 (es)
KR (1) KR101710441B1 (es)
CN (1) CN108472257B (es)
CA (1) CA3009468C (es)
CO (1) CO2018007821A2 (es)
ES (1) ES2868602T3 (es)
MX (1) MX383201B (es)
MY (1) MY194591A (es)
PE (1) PE20181374A1 (es)
PH (1) PH12018501392A1 (es)
RU (1) RU2736942C2 (es)
WO (1) WO2017116150A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
PT1814527E (pt) * 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
GB0600709D0 (en) 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
EP2063888A4 (en) * 2006-09-05 2009-11-04 Astrazeneca Ab PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN CILEXETIL
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
PT2165702E (pt) * 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
KR20100048137A (ko) * 2008-10-30 2010-05-11 현대약품 주식회사 혈압 강하용 약학 조성물
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
KR20090065510A (ko) * 2009-03-13 2009-06-22 다이이찌 산쿄 가부시키가이샤 올메사탄 메독소밀 및 암로디핀의 고형 투여 제형
KR20120096920A (ko) 2009-06-26 2012-08-31 데이진 화-마 가부시키가이샤 고혈압증 또는 정상 고치 혈압증의 치료약
KR101171375B1 (ko) * 2010-01-20 2012-08-13 한올바이오파마주식회사 난용성 약물을 함유하는 경구 제형
CN101966181A (zh) * 2010-07-08 2011-02-09 王丽燕 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
KR101168136B1 (ko) * 2011-08-08 2012-07-24 보령제약 주식회사 혈압 강하용 약제학적 조성물
CN102349902B (zh) * 2011-08-19 2013-05-01 海南锦瑞制药股份有限公司 一种含有左旋氨氯地平和坎地沙坦酯的药物组合物及其制备方法
CN102688236B (zh) * 2012-06-06 2014-03-26 石药集团中诺药业（石家庄）有限公司 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法
KR101302883B1 (ko) * 2012-07-23 2013-09-05 삼일제약주식회사 텔미사르탄을 유효성분으로 포함하는 안정성이 증가된 약제학적 조성물 및 그 제조방법
MX351059B (es) * 2012-08-17 2017-09-29 Laboratorios Senosiain S A De C V Star Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
PL236001B1 (pl) * 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję

Also Published As

Publication number Publication date
PH12018501392A1 (en) 2019-02-27
CN108472257B (zh) 2020-12-04
RU2736942C2 (ru) 2020-11-23
CA3009468A1 (en) 2017-07-06
EP3398589B1 (en) 2021-01-27
BR112018013121A2 (pt) 2018-12-11
RU2018126354A (ru) 2020-01-31
WO2017116150A1 (ko) 2017-07-06
CO2018007821A2 (es) 2018-08-10
ES2868602T3 (es) 2021-10-21
JP6797924B2 (ja) 2020-12-09
MX2018007976A (es) 2019-03-28
RU2018126354A3 (es) 2020-05-12
CA3009468C (en) 2024-06-25
CN108472257A (zh) 2018-08-31
MX383201B (es) 2025-03-13
EP3398589A4 (en) 2019-08-28
MY194591A (en) 2022-12-05
EP3398589A1 (en) 2018-11-07
JP2019500392A (ja) 2019-01-10
US20190015339A1 (en) 2019-01-17
KR101710441B1 (ko) 2017-02-28

Similar Documents

Publication Publication Date Title
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
CL2015002148A1 (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
MX2017002737A (es) Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico